Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

Inclusion Criteria: * Patients meeting DSM-IV-TR criteria for schizophrenia * PANSS total score \<= 120 during the observation period * Patients who have been treated with oral antipsychotics within 4 weeks before informed consent * Patients whose consent is obtained from themselves in written form Exclusion Criteria: * Patients who have defined as any mental disorder other than "Schizophrenia" based on the criteria of DSM-IV-TR * History of drug or alcohol abuse * Concurrent Parkinson's disease * History of, or concurrent spastic disorders like epilepsy, cerebrovascular disease, anuresis or adynamic(= paralytic) ileus, malignant syndrome, diabetes, hepatic disorder * Patients who exhibit abnormalities on Physical Examination, have abnormal vital signs, ECG, or clinical laboratory values * Current cataract during the observation period * History of shock or anaphylactoid symptoms to drugs The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.